Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
IQVIA Holdings's 3-Year RORE % for the quarter that ended in Mar. 2026 was 3.30%.
The industry rank for IQVIA Holdings's 3-Year RORE % or its related term are showing as below:
LTS:0JDM's 3-Year RORE % is ranked better than 60.4% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: -7.79
vs LTS:0JDM: 3.30
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
IQVIA Holdings 3-Year RORE % Related Terms
IQVIA Holdings 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for IQVIA Holdings's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0JDM vs WAT, ILMN, NTRA: 3-Year RORE % Comparison
For the Diagnostics & Research subindustry, IQVIA Holdings's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IQVIA Holdings 3-Year RORE % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IQVIA Holdings's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where IQVIA Holdings's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
IQVIA Holdings (LTS:0JDM) has a 3-Year RORE % of 3.30 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on IQVIA Holdings and its competitors. According to the industry distribution chart, IQVIA Holdings ranks #80 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 39.6%.
Is IQVIA Holdings' 3-Year RORE % too high?
IQVIA Holdings' current 3-Year RORE % is 3.30. Based on the distribution chart, IQVIA Holdings ranks #80 out of 202 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, IQVIA Holdings has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IQVIA Holdings' 3-Year RORE % compare to WAT and ILMN?
According to the Medical Diagnostics & Research industry distribution chart, IQVIA Holdings ranks #80 out of 202 companies for 3-Year RORE %. This puts IQVIA Holdings in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Diagnostics & Research company?
A good 3-Year RORE % depends on the Medical Diagnostics & Research industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on IQVIA Holdings and its competitors. IQVIA Holdings's current 3-Year RORE % is 3.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IQVIA Holdings stock overvalued right now?
Based on GuruFocus' analysis, IQVIA Holdings (LTS:0JDM) is currently considered Modestly Undervalued. The stock's GF Value™ is $248.75, compared to a current price of $207.00 — trading 16.8% below its estimated fair value. The current 3-Year RORE % is 3.30. IQVIA Holdings' overall GF Score™ is 88/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For IQVIA Holdings (LTS:0JDM), the current 3-Year RORE % is 3.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IQVIA Holdings (LTS:0JDM) Overvalued in 2026?
Based on GuruFocus' analysis, IQVIA Holdings stock appears to be undervalued.
The current stock price of $207.00 is trading 16.8% below its estimated GF Value™ of $248.75.
GuruFocus considers IQVIA Holdings to be Modestly Undervalued.
Key valuation signals for LTS:0JDM:
3-Year RORE %: 3.30
GF Value™: $248.75 vs. price of $207.00 (16.8% below fair value)
No single metric tells the full story. See the LTS:0JDM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
88GF Score
Get the complete analysis for LTS:0JDM
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0JDM has been successfully added to your 
